Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GLUE
stocks logo

GLUE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
15.51M
-74.43%
-0.324
-219.86%
6.10M
-92.82%
-0.465
-181.58%
6.10M
-73.7%
-0.480
+220%
Estimates Revision
The market is revising Upward the revenue expectations for Monte Rosa Therapeutics, Inc. (GLUE) for FY2025, with the revenue forecasts being adjusted by 2.01% over the past three months. During the same period, the stock price has changed by 249.39%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+61.67%
In Past 3 Month
Stock Price
Go Up
up Image
+249.39%
In Past 3 Month
Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.260
sliders
Low
16.00
Averages
18.00
High
20.00
Current: 17.260
sliders
Low
16.00
Averages
18.00
High
20.00
Wedbush
Robert Driscoll
Buy
Maintains
$15 → $17
2025-03-21
Reason
Wedbush
Robert Driscoll
Price Target
$15 → $17
2025-03-21
Maintains
Buy
Reason
Wedbush raised the firm's price target on Monte Rosa Therapeutics to $17 from $15 and keeps an Outperform rating on the shares after the company reported Q4 financials and provided clinical updates for its VAV1 and MRT-2359 programs in immunology and oncology, respectively. Monte Rosa shared healthy volunteer data for its MRT-6160 VAV1 degrader program showing a favorable safety profile, along with deep VAV1 degradation of over 90% and substantial ablation of T and B cell function shown by reduction in cytokine release from T and B cells following ex vivo stimulation, the firm notes. Taken together, Wedbush sees these data as providing robust support for further evaluation of the molecule in Phase 2 studies in immune mediated diseases, including autoimmune indications such as colitis and rheumatoid arthritis.
Wells Fargo
Derek Archila
Hold
Maintains
$11 → $10
2025-03-21
Reason
Wells Fargo
Derek Archila
Price Target
$11 → $10
2025-03-21
Maintains
Hold
Reason
Wells Fargo analyst Derek Archila lowered the firm's price target on Monte Rosa Therapeutics to $10 from $11 and keeps an Equal Weight rating on the shares. The firm likes the progress on MRT-6160 and believes it increases the odds of future milestones and royalties. That said, Monte Rosa Therapeutics' programs remain early and with limited catalysts in the near term, Wells expects shares to be range bound.
Wells Fargo
Derek Archila
Buy
to
Hold
Downgrades
$14 → $11
2024-12-19
Reason
Wells Fargo
Derek Archila
Price Target
$14 → $11
2024-12-19
Downgrades
Buy
to
Hold
Reason
Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics to Equal Weight from Overweight with a price arget of $11, down from $14. The firm thinks the stock's upside is limited in 2025 given MRT-6160 is now partnered and the MRT-2359 Phase 1 update in Q1 may have too few patients to fully interpret its profile. As such, Monte Rosa shares are likely to be range bound in 2025, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Monte Rosa Therapeutics Inc (GLUE.O) is -10.02, compared to its 5-year average forward P/E of -4.71. For a more detailed relative valuation and DCF analysis to assess Monte Rosa Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.71
Current PE
-10.02
Overvalued PE
-1.24
Undervalued PE
-8.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.25
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.50
Undervalued EV/EBITDA
-6.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.92
Current PS
0.00
Overvalued PS
22.74
Undervalued PS
-2.91
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

GLUE News & Events

Events Timeline

(ET)
2025-11-09
13:15:09
Monte Rosa Therapeutics unveils preclinical findings on MRT-8102
select
2025-11-06 (ET)
2025-11-06
07:03:26
Monte Rosa Therapeutics projects funding to last until 2028
select
2025-11-06
07:03:04
Monte Rosa Therapeutics Announces Q3 Revenue of $12.8M, Exceeding Consensus Estimate of $7.37M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
17:00 PMNASDAQ.COM
GLUE Surpasses Average Analyst Price Target

  • Stock Performance: Monte Rosa Therapeutics Inc (GLUE) shares have surpassed the average analyst 12-month target price of $17.20, currently trading at $17.26/share.

  • Analyst Reactions: Analysts may respond to the stock reaching the target price by either downgrading their valuation or raising their target price, depending on the company's fundamental developments.

  • Diverse Analyst Targets: Within the Zacks coverage universe, analyst targets for GLUE vary significantly, with one as low as $13.00 and another as high as $20.00, indicating a standard deviation of $2.774.

  • Investor Considerations: The crossing of the average target price signals investors to evaluate whether the stock's valuation is justified or if it may be time to consider selling some shares.

[object Object]
Preview
9.0
11-09Newsfilter
Monte Rosa Therapeutics Unveils Preclinical Findings on MRT-8102, a NEK7-targeted Molecular Glue Degrader, for Treating Cardiovascular and Cardiometabolic Conditions at AHA Scientific Sessions 2025

  • MRT-8102 Overview: Monte Rosa Therapeutics is developing MRT-8102, a first-in-class NEK7-directed molecular glue degrader aimed at treating inflammatory diseases linked to the NLRP3 inflammasome, with potential applications in cardiovascular and cardiometabolic diseases such as pericarditis and atherosclerosis.

  • Phase 1 Study Progress: Initial data from a Phase 1 study involving healthy volunteers and individuals at elevated cardiovascular disease risk is expected to be presented in the first half of 2026, highlighting the ongoing development of MRT-8102.

  • Mechanism of Action: MRT-8102 has shown the ability to inhibit the NLRP3 inflammasome and reduce the release of inflammatory cytokines, demonstrating a unique approach to modulating inflammation compared to existing therapies.

  • Presentation Details: Preclinical data on MRT-8102 will be presented at the American Heart Association's Scientific Sessions 2025, emphasizing its potential as a novel therapeutic strategy for cardiovascular inflammation.

[object Object]
Preview
9.0
10-01TipRanks
Novartis Shares Surge Following U.S. Approval of Pill for Persistent Skin Flare-Ups

  • Approval of Rhapsido: Novartis has received U.S. FDA approval for Rhapsido, a new oral treatment for chronic spontaneous urticaria (CSU) in adults, which is expected to enhance its market presence in the U.S.

  • Business Expansion and Market Response: The approval has positively impacted Novartis's stock, which rose 0.4%, and comes alongside significant business moves, including a $5.7 billion deal with Monte Rosa and plans to sell Cosentyx at a discount starting November 1.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Monte Rosa Therapeutics Inc (GLUE) stock price today?

The current price of GLUE is 17.26 USD — it has increased 2.37 % in the last trading day.

arrow icon

What is Monte Rosa Therapeutics Inc (GLUE)'s business?

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

arrow icon

What is the price predicton of GLUE Stock?

Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Monte Rosa Therapeutics Inc (GLUE)'s revenue for the last quarter?

Monte Rosa Therapeutics Inc revenue for the last quarter amounts to 12.77M USD, increased 38.54 % YoY.

arrow icon

What is Monte Rosa Therapeutics Inc (GLUE)'s earnings per share (EPS) for the last quarter?

Monte Rosa Therapeutics Inc. EPS for the last quarter amounts to -0.33 USD, increased 13.79 % YoY.

arrow icon

What changes have occurred in the market's expectations for Monte Rosa Therapeutics Inc (GLUE)'s fundamentals?

The market is revising Upward the revenue expectations for Monte Rosa Therapeutics, Inc. (GLUE) for FY2025, with the revenue forecasts being adjusted by 2.01% over the past three months. During the same period, the stock price has changed by 249.39%.
arrow icon

How many employees does Monte Rosa Therapeutics Inc (GLUE). have?

Monte Rosa Therapeutics Inc (GLUE) has 134 emplpoyees as of December 05 2025.

arrow icon

What is Monte Rosa Therapeutics Inc (GLUE) market cap?

Today GLUE has the market capitalization of 1.12B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free